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Abstract
Currently, the neuropathological diagnosis of Lewy body disease (LBD) may be stated according to several staging sys-
tems, which include the Braak Lewy body stages (Braak), the consensus criteria by McKeith and colleagues (McKeith), the 
modified McKeith system by Leverenz and colleagues (Leverenz), and the Unified Staging System by Beach and colleagues 
(Beach). All of these systems use semi-quantitative scoring (4- or 5-tier scales) of Lewy pathology (LP; i.e., Lewy bodies 
and Lewy neurites) in defined cortical and subcortical areas. While these systems are widely used, some suffer from low 
inter-rater reliability and/or an inability to unequivocally classify all cases with LP. To address these limitations, we devised a 
new system, the LP consensus criteria (LPC), which is based on the McKeith system, but applies a dichotomous approach for 
the scoring of LP (i.e., “absent” vs. “present”) and includes amygdala-predominant and olfactory-only stages. α-Synuclein-
stained slides from brainstem, limbic system, neocortex, and olfactory bulb from a total of 34 cases with LP provided by 
the Newcastle Brain Tissue Resource (NBTR) and the University of Pennsylvania brain bank (UPBB) were scanned and 
assessed by 16 raters, who provided diagnostic categories for each case according to Braak, McKeith, Leverenz, Beach, and 
LPC systems. In addition, using LP scores available from neuropathological reports of LP cases from UPBB (n = 202) and 
NBTR (n = 134), JT (UPBB) and JA (NBTR) assigned categories according to all staging systems to these cases. McKeith, 
Leverenz, and LPC systems reached good (Krippendorff’s α ≈ 0.6), while both Braak and Beach systems had lower (Krip-
pendorff’s α ≈ 0.4) inter-rater reliability, respectively. Using the LPC system, all cases could be unequivocally classified by 
the majority of raters, which was also seen for 97.1% when the Beach system was used. However, a considerable proportion 
of cases could not be classified when using Leverenz (11.8%), McKeith (26.5%), or Braak (29.4%) systems. The category 
of neocortical LP according to the LPC system was associated with a 5.9 OR (p < 0.0001) of dementia in the 134 NBTR 
cases and a 3.14 OR (p = 0.0001) in the 202 UPBB cases. We established that the LPC system has good reproducibility and 
allows classification of all cases into distinct categories. We expect that it will be reliable and useful in routine diagnostic 
practice and, therefore, suggest that it should be the standard future approach for the basic post-mortem evaluation of LP.
Keywords Lewy body disease · Diagnostic neuropathology
Introduction
Lewy body disease (LBD) encompasses Parkinson’s dis-
ease (PD), PD with mild cognitive impairment (PD-MCI), 
PD with dementia (PDD), and dementia with Lewy bodies 
(DLB), which all have a characteristic clinical presentation 
and associated clinical diagnostic criteria [10, 15, 18, 23]. 
The neuropathological hallmark of these clinically defined 
conditions is Lewy pathology (LP), which encompasses 
α-synuclein aggregates in nerve cell bodies and processes: 
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Lewy bodies (LB) and Lewy neurites (LN), respectively. 
However, LP may also be seen in individuals lacking distinct 
clinical symptoms. The term incidental LBD was initially 
coined for individuals who lacked Parkinsonian or cognitive 
symptoms but had minimal LP restricted to the brainstem, 
but more recently, it has been expanded to encompass amyg-
dala-predominant and olfactory-only LP [2, 3, 13].
The heterogeneity of LP is a challenge for neuropatho-
logical classification systems. Diagnostic categories must 
reflect the wide range of LP severity and anatomical dis-
tribution, while also enabling robust inter-rater reliability. 
The existing neuropathological classification systems used 
for the diagnosis and staging of LP include the Braak LB 
stages (Braak) [5], the DLB consensus criteria published by 
McKeith and colleagues (McKeith) [17], the modified DLB 
consensus criteria by Leverenz and colleagues (Leverenz) 
[14], and the Unified Staging System for LBD by Beach 
and colleagues (Beach) [3]. These staging systems are based 
on the semi-quantitative scoring of LBs and LNs in neuro-
anatomically defined regions, in particular the dorsal motor 
nucleus of the vagal nerve, locus coeruleus, substantia nigra, 
transentorhinal cortex, amygdala, cingulate cortex, temporal 
cortex, frontal cortex, and parietal cortex. For the McKeith, 
Leverenz, and Beach systems the severity of LBs and LNs is 
scored on a 5-tier scale: 0 = absent, 1 = sparse LBs or LNs, 
2 = more than one LB per high power field and sparse LNs, 
3 = more than four LBs and scattered LNs in a low power 
field, 4 = numerous LBs and LNs, as illustrated by McKeith 
and colleagues [17]. For the Braak system, a four-tier scale 
is used to reflect the extent of α-synuclein immunolabel-
ling: 0 = absent, 1 = “slight”, 2 = “moderate”, 3 = “severe”, 
as described by Braak and colleagues [5].
The BrainNet Europe Consortium (BNE) found mean 
inter-rater agreement rates of 65% (range 32–100%) for 
the Braak system and 81% (range 45–100%) for the McK-
eith system when 22 experts assessed 31 cases which all 
showed some LB pathology [2]. BNE developed a new 
protocol which was not based on semi-quantitative scoring 
but simply on the presence or absence of LBs and/or LNs, 
and added the category “amygdala predominant” for cases 
with pathology most severe in the amygdala and less pro-
nounced in brainstem areas. This protocol achieved inter-
rater agreement of 83% for the Braak system and 84% for 
the McKeith system [2]. Similarly, Müller and colleagues 
applied the Braak system in an inter-rater study where a 
semi-quantitative score was only needed for stage 6, while 
stages 1–5 could be assigned based on the presence of LP 
in the relevant areas and achieved an inter-rater reliability 
of at least 76% [20].
While all of these neuropathological staging systems are 
widely used, they exhibit relatively low inter-rater reliabil-
ity and frequently make cases diagnostically unclassifiable; 
e.g., a case with severe LP in the neocortex but only mild in 
the brainstem cannot be classified in the Braak system and 
when using the McKeith system cases may sometimes be 
assigned to more than one category. Hence, there is a need 
for a LP staging system that shows high inter-rater reliabil-
ity, allows for the unequivocal classification of all possible 
cases, and is readily applicable in neuropathological routine 
diagnostics. To address this unmet need, we developed a 
new LP classification system based on a modification of the 
McKeith system and which uses the dichotomized approach 
introduced by the BNE. 16 raters in 13 different centres used 
this new classification system as well as the Braak, McK-
eith, Leverenz, and Beach systems to score and stage LP 
in 34 cases. In addition, regional LP scores retrieved from 
diagnostic neuropathological reports from the University of 
Pennsylvania brain bank (UPBB) and the Newcastle Brain 
Tissue Resource (NBTR) were used to re-assign LP catego-
ries according to all systems for 363 LP cases.
Materials and methods
Classification system
Our proposed new neuropathological classification system 
for LP, the LP consensus criteria (LPC), is based on dichoto-
mized scoring of LB or LN, i.e. as present ( +) or absent 
( −), in olfactory bulb, dorsal motor nucleus of the vagal 
nerve (dmX), substantia nigra, amygdala, cingulate cortex, 
medial–temporal cortex, frontal cortex, and parietal cortex 
(Fig. 1). A region is scored positive if the severity of LB or 
LN would be at least scored 1 (sparse LBs or LNs) accord-
ing to the McKeith system (Fig. 2) [17]. The possible diag-
nostic categories are olfactory-only, amygdala-predominant, 
brainstem, limbic, and neocortical LP as suggested in the 
Fourth Consensus Report of the DLB Consortium [18]. Of 
note, all regions need to be assessed, but for the diagnosis 
of brainstem, limbic, and neocortical LP not all regions that 
are characteristic for the respective LP group need to be 
positive: e.g., a case with a LB or LN score of 1 in either 
frontal or parietal cortex would be classified as neocortical 
LP (Fig. 1). 
Neuropathological samples
Human post-mortem brain tissue for the multi-rater assess-
ment included 34 cases showing varying degrees of LP was 
obtained from the NBTR, (n = 13), with the approval of the 
joint Ethics Committee of Newcastle and North Tyneside 
Health Authority and in accordance with NBTR brain bank-
ing procedures, and from the UPBB (n = 21). None of the 
cases had any indication for a genetic synucleinopathy.
At NBTR, the right hemisphere, brainstem, and cer-
ebellum were immersion-fixed in 4% aqueous formalin for 
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4–6 weeks. Routine tissue blocks were dissected for neuro-
pathological diagnosis. The blocks were processed through 
increasing concentrations of alcohol and chloroform before 
being embedded in paraffin wax. Sections were cut at 
6 μm. Those for immunohistochemistry underwent antigen 
retrieval and were incubated with antibody to α-synuclein 
(KM51 clone, 1:200. Leica, UK), which detects full length 
α-synuclein. Pathological protein aggregates were visual-
ised using the Menarini X-Cell-Plus HRP Detection Kit 
(Menarini, Berkshire, UK), with 3,3′-diaminobenzidine as 
the chromogen.
At UPBB tissue was fixed in 10% neutral buffered for-
malin for one set of blocks, and 70% ethanol with 150 mM 
NaCl for another set of blocks (for details see [29]). One 
hemisphere was cut coronally at 1–1.5 cm intervals and cor-
tical and subcortical blocks were taken. The brainstem was 
cut perpendicular to the neuraxis and cerebellum parasagit-
tal at 1 cm intervals. The day after the autopsy, the tissue 
blocks were placed in cassettes and they are embedded in 
paraffin wax and cut at 6–10 μm for histology. Syn303 (mAb, 
1:16,000, generated in the CNDR) was used to detect the 
presence of pathological α-synuclein (epitopes with amino 
acid residues 2–4). Bound primary antibody was visualized 
by the avidin–biotin detection method (VECTASTAIN ABC 
kit; Vector Laboratories, Burlingame, CA) with ImmPACT 
diaminobenzidine peroxidase substrate (Vector Laborato-
ries) as the chromogen [29].
Multi‑rater assessment
Immunohistochemical sections (α-synuclein) that included 
dmX (medulla section), substantia nigra, amygdala, cin-
gulate gyrus, medial-temporal cortex (parahippocampal 
gyrus), frontal cortex and parietal cortex from all 34 cases 
and from 13 olfactory bulbs (NBTR cases) were scanned 
using a Leica SCN 400 scanner at 40 × magnification (Sup-
plementary Table 1, online resource). The scanned images, 
which included the entire section, were uploaded to a server 
Fig. 1  The new Lewy pathology consensus criteria (LPC). Yellow 
colour, LP can be absent ( −) or present ( +); red colour, LP must 
be present ( +). Of note: while presence ( +) of LP in the amygdala 
and in medial–temporal lobe or cingulate cortex is not mandatory for 
assigning a category of limbic and neocortical LP, respectively, we 
emphasise that it is highly unlikely that LP will be absent ( −) in the 
amygdala of limbic LP and in the medial–temporal lobe or cingulate 
cortex of neocortical LP. LP Lewy-related pathology; OB olfactory 
bulb/tract; dmX dorsal motor nucleus of vagal nerve/ medulla; SN 
substantia nigra; Amy amygdala; MTL medial–temporal cortex; Cing 
cingulate cortex; Fr. or Pa. ctx, frontal or parietal cortex
 Acta Neuropathologica
1 3
and assessed by 16 raters (BS, DRT, EG, GH, GK, JA, JBT, 
JQT/EBL, KEM, LP, LTG, LW, MN, SL, TH, and TP); the 
Leica software (Aperio ImageScope, version 11.2) allowed 
for virtual slide navigation across the entire section and mag-
nification comparable to a 40 × objective on a microscope 
(approx. 400 × magnification), so that even small neurites 
could be detected. The raters were blinded to any clinical or 
neuropathological diagnosis and by following the respective 
scoring and staging guidelines [3, 5, 14, 17], they assigned 
each case to a category within the Braak, McKeith, Lev-
erenz, Beach, and LPC systems. In addition, raters’ scores 
were used to assign categories according to the dichoto-
mized method suggested by BrainNet Europe for Braak and 
McKeith systems [2].
Re‑classification of archival cases
202 cases from UPBB and 134 cases from NBTR were 
assigned to a category according to Braak, McKeith, Lev-
erenz, and LPC systems, using the semi-quantitative scores 
already available from the initial diagnostic assessment. The 
assignment was performed blinded to the original diagno-
ses by JBT for UPBB cases and JA for NBTR cases. Of 
note, none of the cases was initially diagnosed with a genetic 
synucleinopathy.
Statistical analysis
The median was used as a measure of central tendency and 
the 25th and 75th percentiles to evaluate variability. We used 
Krippendorff’s α, as opposed to Cohen’s κ which is often 
used in multi-site assessments (e.g., for NIA-AA guidelines 
[19]), because the former allows for missing data (non-
classifiable cases, were not considered to have an assign-
able stage) and, like Fleiss’ kappa, is capable of including 
multiple raters in a single statistic. We did not use weighted 
statistics as we did not assume that there is a single order 
for ordering the categories. Therefore, all the possible dif-
ferences in staging assignments between raters had the same 
weight/impact on the score. Logistic regression was used to 
assess the odds of a dementia diagnosis at the time of death 
Fig. 2  Photomicrographs of α-synuclein stained slides showing dot 
like, artefactual positivity that should not be considered positive for 
scoring (encircled in a and b) and single α-synuclein-positive Lewy 
neurites (arrows in c and d) that would yield a score of “positive”. 
Scale bar in a: 70 μm, in b, c, and d: 50 μm
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when cases were subdivided according to limbic versus neo-
cortical LPC stages, after adjusting for the Braak neurofibril-
lary tangle stage (V/VI versus lower stages).
Results
Inter‑rater evaluation of staging systems
Supplementary Figs. 1–9 (online resource) show the semi-
quantitative scores assigned to each area of the 34 cases. 
Overall, inter-rater reliability was moderate to high, with 
lowest reliability for the amygdala, medulla and olfactory 
bulb sections (Fig. 3a).
Based on their semi-quantitative scores raters classified 
each case according to the five staging systems. Overall, 
McKeith (Krippendorff’s α: 0.59), Leverenz (Krippen-
dorff’s α: 0.59), and LPC (Krippendorff’s α: 0.59) systems 
reached good inter-rater reliability, whereas Braak (Krip-
pendorff’s α: 0.39) and Beach (Krippendorff’s α: 0.41) 
systems had lower reliability (Fig. 3b). There were con-
siderable differences between the staging systems in the 
percentage of cases that were not assigned any stage and, 
therefore, deemed non-classifiable by the majority of 
raters, with LPC (0%), and Beach (2.9%) systems perform-
ing best, followed by Leverenz (11.8%), McKeith (26.5%) 
and Braak (29.4%) systems (Fig. 3c).
Figure 4 presents the individual stages assigned to each 
case by the raters. Table 1 shows for each case the cat-
egories that reached highest agreement together with the 
percentage of raters who assigned this category as well as 
the mean agreement rates for each classification system. 
100% agreement (including a ‘non-classifiable’ category) 
was reached in 14.7% of cases for Braak, 26.5% for McK-
eith, 8.8% for Leverenz, 11.8% for Beach, and 29.4% for 
LPC systems. Of note, when non-classifiable cases were 
Fig. 3  Inter-rater reliability 
(Krippendorff’s α) for semi-
quantitative scores (a) and 
diagnostic categories assigned 
using the different staging 
systems (b). Percentages of 
cases that were deemed non-
classifiable by the majority of 




Fig. 4  Percentages of assigned diagnostic categories according to Braak (a), McKeith (b), Leverenz (c), Beach (d) and LPC (e) systems. X-axis 
shows individual case numbers
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Table 1  Percentages of highest agreement in assigned categories
Case Braak McKeith Leverenz Beach LPC Clinical
Diagnosis
Case 1 37.5% St. 4/ n.c 100% Limb 87.5% Lim 62.5% Lim.pr 100% Lim Dementia
FTD
Case 2 56.25% St. 6 56.25% Neoc 93.75% Lim 50% Brst.lim 81.25% Neoc Dementia
PDD
Case 3 87.5% St. 6 100% Neoc 100% Neoc 100% Neoc 100% Neoc Dementia
PDD
Case 4 87.5% St. 6 100% Neoc 93.75% Neoc 100% Neoc 100% Neoc Dementia
PDD
Case 5 100% n.c 87.5% n.c 93.75% Amy 75% Lim.pr 56.25% Amy.pr Dementia
AD
Case 6 100% n.c 93.75% n.c 68.75% Amy 68.75% Lim.pr 68.75% Amy.pr Dementia
AD
Case 7 81.25% St. 6 87.5% Neoc 81.25% Lim 56.25% Neoc 87.5% Neoc Dementia
PDD
Case 8 43.75% St. 5 68.75% Lim 93.75% Lim 56.25% Brst. pr 68.75% Lim No Dem
PD
Case 9 31.25% St. 4/ n.c 62.5% Lim 93.75% Lim 37.5% Lim.pr 50% Lim No Dem
MSA
Case 10 93.75% St.6 93.75% Neoc 81.25% Neoc 81.25% Neoc 93.75% Neoc Dementia
AD
Case 11 93.75% St. 6 100% Neoc 87.5% Neoc 87.5% Neoc 100% Neoc Dementia
DLB
Case 12 50% St. 4 93.75% Lim 93.75% Lim 68.75% Brst.lim 68.75% Lim No Dem
PD
Case 13 43.75% n.c 43.75% n.c 56.25% Lim 50% Brst.lim 50% Brst Dementia
AD
Case 14 37.5% n.c 68.75% Lim 56.25% Lim 68.75% Brst.lim 87.5% Lim Dementia
ADD
Case 15 81.25% St. 6 93.75% Neoc 100% Neoc.l 87.5% Neoc 100% Neoc Dementia
PDD
Case 16 50% n.c 50% n.c 93.75% Lim 68.75% Brst.lim 81.25% Neoc Dementia
ADD
Case 17 62.5% St. 6 62.5% Neoc 43.75% Neoc 43.75% Neoc 87.5% Neoc Dementia
PDD
Case 18 50% St. 6 50% Lim 93.75% Lim 50% Neoc 75% Neoc Dementia
DLB
Case 19 87.5% St. 6 100% Neoc 81.25% Neoc 87.5% Neoc 100% Neoc Dementia
PDD
Case 20 87.5% n.c 68.75% n.c 56.25% Amy 68.75% Lim.pr 62.5% Lim Dementia
ADD
Case 21 81.25% St. 6 100% Neoc 93.75% Neoc 100% Neoc 100% Neoc Dementia
PDD
Case 22 43.75% St. 3 81.25% Brst 81.25% Brst 56.25% Brst.pr 62.5% Brst No Dem
Control
Case 23 43.75% St. 3 56.25% Brst 62.5% Brst 0% Brst.pr 93.75% Brst No Dem
Control
Case 24 31.25% St. 4 50% Brst 50% Lim 50% Brst.pr 50% Lim No Dem
Control
Case 25 62.5% St. 4 50% Lim 93.75% Lim 62.5% Brst.lim 68.75% Lim Dementia AD/DLB
Case 26 46.67% St. 4 93.33% Brst 93.33% Brst 53.33% Brst.pr 66.67% Brst No Dem
Control




excluded from the calculation, 100% agreement was never 
reached when using the Braak system (Table 1).
When Braak and McKeith categories were assigned using 
the dichotomized BrainNet Europe method, the inter-rater 
reliability increased for Braak (Krippendorff’s α: 0.47), 
while it remained virtually unchanged for McKeith (Krip-
pendorff’s α: 0.57) systems. For both Braak and McKeith 
systems, the percentage of cases that were not classifiable 
decreased to 20.6% and 17.6% and 100% agreement rates 
increased considerably to 32.4% and 38.2%, respectively 
(Supplementary table 2, online resource).
Evaluation of staging schemes in UPBB and NBTR 
archival cases
We evaluated 202 UPBB and 134 NBTR archival cases. The 
most common clinic-pathological diagnoses were AD, DLB, 
PD and PDD. Figure 5 summarizes the neuropathological 
diagnoses, stratified by clinical diagnosis, assigned to the 
UPBB and NBTR cases. The Braak and McKeith systems 
yielded the largest number of cases that were non-classi-
fiable, mainly for the AD dementia and “other diagnoses” 
group (59.3–69.9% for Braak and 41.2–81.6% for McKeith 
systems). The number of non-classifiable cases for the PD/
PDD and DLB groups was lower for both systems (2.4–40% 
for Braak and 13.3%-40% for McKeith systems). Applying 
the Leverenz system led to a lower number of cases being 
non-classifiable (8.9–23.5% for the AD and “other diagno-
ses” and 0–8.9% for the DLB and PD/PDD). Most cases 
could be classified according to the Beach system (only 2.2% 
of AD and 3% of DLB NBTR cases were non-classifiable). 
All cases were classifiable by the LPC system. In the UPBB, 
two cases were considered to fit within two different Lever-
enz stages and one case to fit within two different McKeith 
stages. A comparison of the staging of cases in the different 
systems is summarized in Supplementary Tables 3 (UPBB) 
and 4 (NBTR).
Supplementary Tables 5 (UPBB; online resource) and 6 
(NBTR; online resource) show the association between the 
different LPC categories and a dementia diagnosis. A pos-
sible limitation of the LPC is that the low neuropathological 
threshold needed to classify subjects as neocortical stage 
could lead to an “overcalling” of neocortical stages. To eval-
uate this possibility, we stratified cases by Braak neurofibril-
lary tangle stage and compared the odds of being demented 
at the time of death in patients with limbic versus neocortical 
LPC stages. Thus we evaluated if the neocortical stage was 
associated with greater odds of dementia compared to the 
limbic stage. The neocortical LPC stage was indeed associ-
ated with a 3.14 OR (p = 0.0001) of dementia in UPBB cases 
and a 5.0 OR (p < 0.0001) in NBTR cases. The difference 
between these ORs may be partly explained by differences 
Table 1  (continued)
Case Braak McKeith Leverenz Beach LPC Clinical
Diagnosis
Case 28 33.33% n.c 46.67% Brst./ n.c 66.67% Brst 33.33% Brst.lim 73.33% Brst No Dem
Control
Case 29 100% n.c 100% n.c 86.67% n.c 80% Olf 80% Olf.only Dementia
AD
Case 30 100% n.c 93.33% n.c 86.67% Amy 73.33% Lim.pr 100% Amy.pr Dementia
AD
Case 31 93.33% St. 6 100% Neoc 100% Neoc 100% Neoc 100% Neoc Dementia
AD/DLB
Case 32 86.67% St. 6 93.33% Neoc 46.67% Lim./ Neoc 80% Neoc 100% Neoc Dementia
AD/DLB
Case 33 66.67% St. 6 73.33% Neoc 60% Neoc 60% Neoc 93.33% Neoc Dementia
DLB
Case 34 100% n.c 100% n.c 93.33% n.c 93.33% Olf 93.33% Olf.only Dementia
AD
Mean agreement 69% 79.80% 79.90% 68.50% 81%
100% agreement includ-
ing n.c
14.7% 26.5% 8.8% 11.8% 29.4%
100% agreement exclud-
ing n.c
0% 29.2%% 9.4% 11.8% 29.4%
AD Alzheimer’s disease; Amy amygdala; Amy.pr amygdala predominant; Beach, Unified Staging System for LBD by Beach and colleagues [3]; 
Braak, Lewy body Braak stages [5], Brst., brainstem; Brst.lim brainstem-limbic; Brst.pr brainstem predominant; DLB Dementia with Lewy 
bodies; FTD Frontotemporal dementia; Leverenz modified DLB consensus criteria by Leverenz and colleagues [10] lim. limbic; lim.pr limbic 
predominant; LRPC Lewy-related pathology consensus criteria; McKeith DLB Consensus Criteria by McKeith and colleagues [13]; Neoc. neo-
cortical; n.c, non-classifiable; Olf olfactory; PD Parkinson’s disease; PDD, PD dementia
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in clinic-pathological diagnoses in the cohorts; in the UPBB 
cohort 9.5% and 28.6.% of cases had a clinic-pathological 
diagnosis of DLB and PD/PDD, respectively, while the 
NBTR cohort had a considerably higher percentage of DLB 
(37.8%) and completely lacked PD/PDD (Supplementary 
Table 1, online resource).
Discussion
We have devised and tested a new staging system for the 
assessment of LP. Our proposed LPC system was applied 
together with previously established Braak, McKeith, Lev-
erenz, and Beach systems, by 16 raters on 34 cases. The 
Fig. 5  Diagnostic categories for 
archival cases of the University 
of Pennsylvania brain bank 
(UPBB; (a) and Newcastle 
Brain Tissue Resource (NBTR; 




LPC system showed good inter-rater reliability: comparable 
to McKeith and Leverenz systems, and considerably better 
than Braak and Beach systems (Fig. 3b). Using the LPC sys-
tem, the majority of raters were able to classify all cases; in 
comparison, while most cases (over 95%) could be classified 
using Beach, over 10% of cases could not be classified using 
Leverenz, over 25% using McKeith and nearly 30% using 
Braak systems, respectively (Fig. 3c). Percentages were even 
higher when UPBB and NBTR archival cases with a clinical 
diagnosis of AD dementia were evaluated (Fig. 5).
Since the initial identification of α-synuclein in LB 
[25], several staging systems have been proposed and 
implemented to classify LP [2, 3, 5, 14, 17]. The Braak 
system was developed to assess the typical patterns of 
Fig. 5  (continued)
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severity and distribution of the LP in PD. However, later 
studies showed divergent patterns of progression in PD 
where the accumulation of pathological α-synuclein 
begins in the brainstem, as opposed to AD or DLB, where 
LP may be limited to limbic and neocortical regions [3, 
30]. This helps explain the relatively high number of non-
classifiable cases observed when applying the Braak sys-
tem in our study. The McKeith system showed a similar 
high percentage of non-classifiable cases, partly reflecting 
the necessity to have at least some brainstem pathology 
to assign any stage, which is also true for the Leverenz 
system. In addition, according to the McKeith system, 
some cases can equally fulfil the criteria for limbic and 
neocortical LP (e.g., brainstem and limbic regions, score 
3; temporal cortex score 2 and frontal cortex score 1); 
consequently, such cases cannot be assigned to just a sin-
gle category and thus are not classifiable. Both Braak [5] 
and McKeith [17] systems were published before it was 
shown that LP may be restricted to the olfactory bulb or 
amygdala [2, 3, 13] and, therefore, such cases cannot be 
assigned a category in both Braak and McKeith systems. 
However, in our study, only three cases were categorized 
as “Amygdala predominant” and one as “Olfactory only”. 
While application of the method suggested by the Brain-
Net Europe [2] resulted in a reduction of percentage rates 
of cases that could not be classified, they were still higher 
than for all other systems.
Assignment of a category in both Braak and Beach sys-
tems depends heavily on the semi-quantitative score for LP 
in each region. Since that is relatively subjective, it is not 
surprising that both Braak and Beach systems had the lowest 
inter-rater reliability in our study (Fig. 3c). Semi-quantitative 
scores are also used in McKeith and Leverenz systems, but 
regional scores may range from 1 to 3 and individual scores 
do not, therefore, influence the assignment of a category as 
much as they do in Braak and Beach systems. We have seen 
a high inter-rater reliability for both McKeith and Leverenz 
systems as well as for our proposed LPC system; the use of 
a dichotomized approach where a region can either be scored 
negative or positive for LP greatly reduces the probability of 
differences in scores between multiple raters. This is further 
supported by our finding of Braak systems showing higher 
inter-rater reliability and both Braak and McKeith system 
showing highest percentage of cases with 100% agreement, 
when the dichotomized method suggested by the Brain-
Net Europe was used. However, 100% agreement was only 
reached in 29.4% when using the LPC system, which is still 
higher than the 100% agreement rates for Braak, McKeith, 
Leverenz, and Beach systems, but admittedly relatively low 
considering the dichotomized scoring and the simple staging 
approach. We assume that the use of only digital images had 
an adverse impact on the scoring accuracy of raters, who 
are used to assessing slides on a microscope, in particular 
since sometimes relatively large areas had to be screened 
for minimal amounts of pathology (e.g., single LNs in a 
neocortical section).
In addition to our multi-rater assessment, we evaluated 
the LPC system in comparison with Braak, McKeith, Lev-
erenz, and Beach systems, in a total of 336 archival cases 
from the UPBB and NBTR: a large sample of consecutive 
non-selected cases with a broad range of clinical diagnoses. 
LP in PD cases with or without cognitive impairment was 
classifiable by all staging systems. However, when demen-
tia was the main presenting feature, LP was not classifiable 
in 41–82% of cases staged according to Braak or McKeith 
systems (Fig. 5). This inability to stage a high proportion of 
cases according to Braak or McKeith systems is in keeping 
with previous findings by Beach and colleagues [3]. Both 
Beach and our proposed LPC system are better suited for the 
classification of LP pathology across the entire spectrum of 
neurodegenerative diseases and ageing.
We scored a region positive if sparse LBs or LNs were 
seen thereby giving equal importance to LBs and LNs for 
assigning the lowest possible positive LP score, which is in 
agreement with previous publications on the assessment of 
LP in post-mortem brains [2, 3, 14, 17]. Hence, our dichoto-
mous LP scoring approach leads to cases with relatively low 
amounts of LP in limbic/neocortical areas being categorised 
as limbic/neocortical LP. While this could in theory possibly 
result in a relatively high proportion of cognitively unim-
paired individuals being diagnosed as having neocortical LP, 
in the multi-rater assessment all 15 cases with neocortical 
LP, as determined by the majority of raters, had a clinical 
diagnosis of dementia. Moreover, in both UPBB and NBTR, 
a LPC category of neocortical LP was associated with sig-
nificantly increased odds of having dementia in life even 
after controlling for neurofibrillary tangle tau pathology. 
However, some α-synuclein antibodies may produce non-
specific immunolabelling [8] and, therefore, we suggest that 
the presence of single dot-like immunopositivity in the neu-
ropil alone in the absence of any neuronal immunopositivity 
is not sufficient to score the section positive (Fig. 2a, b). We 
further suggest that detailed clinico-pathological correlative 
studies should not be based on diagnostic staging systems, 
like the one we present here, but always aim to obtain more 
quantitative measures of the burden of pathological protein 
aggregates (e.g., image analysis).
To make our system applicable for neuropathological rou-
tine diagnostics at relatively low costs, we have deliberately 
limited the number of regions that need to be assessed to an 
absolute minimum and have chosen those regions that have 
been widely used in previous staging systems. However, LP 
in particular in PD, may be present in a variety of tissues 
such as the spinal cord [7], gut [6, 27], sympathetic ganglia 
[26], adrenal gland [11], heart [22], and skin [9] among oth-
ers. The systematic pathological assessment of LP in regions 
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outside the brain may be possible in the future if post-mor-
tem examination related to neurodegeneration routinely 
combines assessment of both cerebral and relevant extra-
cerebral tissues, and will lead to the development of staging 
systems for LP that encompass LP in the entire human body.
In our study, two different antibodies were used, the 
KM51 clone (Leica, UK), which detects full length 
α-synuclein was used for NBTR cases while UPBB cases 
were stained with Syn303 (CNDR) which detects epitopes 
with amino acid residues 2–4. We did not observe any dif-
ferences in inter-rater reliability or ability to classify cases 
between cases from NBTR and UPBB, suggesting that the 
reliability of LPC is not dependent on specific α-synuclein 
antibodies.
The LPC system was devised primarily to increase the 
reliability of diagnostic assessment, without implying any 
particular pattern of topographical spread of pathology, such 
as in the Beach system [1, 3]. Our findings confirm that the 
Beach system, based on the putative pathological processes 
underlying disease progression, allows most cases to be 
staged and is, therefore, a useful scheme if used by experi-
enced raters, although due to the low inter-rater reliability it 
may not practicable for day-to-day routine diagnostics and 
collection of data across brain bank networks. We would 
also note that we did not include the assessment of substan-
tia nigra cell loss in the inter-rater evaluation as this is not 
included in previous LP staging systems and was not within 
the aims of our study. However, we suggest that evaluation 
of substantia nigra cell loss should routinely be performed, 
as previously recommended by the BrainNet Europe Con-
sortium [2]. The Fourth Consensus Report of the DLB Con-
sortium further suggests to score nigral neuronal cell loss to 
subclassify cases into those likely or not to have Parkinson-
ism and the LPC categories can be used to determine the 
likelihood that pathological findings are associated with a 
typical DLB clinical syndrome (Table 2 in [18]).
We used the term LP instead of LBD in the LPC system 
categories and we recommend that the terms PD-MCI, PDD 
or DLB not be used to describe the neuropathological find-
ings alone. These diagnoses should only be made once the 
clinical presentation, including neuropsychological evalua-
tion, is combined with the post-mortem neuropathological 
findings. In addition, as the ageing brain typically includes 
multiple pathologies which together can lower the threshold 
for one specific pathology to cause dementia (or other neuro-
logical impairment) [4, 12, 28], the neuropathological report 
should contain information on all observed pathologies, e.g., 
AD neuropathological change [19], TDP-43 pathology [16, 
21], cerebrovascular pathology [24], and LP.
We conclude that the LPC system is a useful clas-
sification system for LP. It has good reproducibility and 
clinical utility, and our expectation is that it will be reli-
able and useful in routine diagnostic practice, allowing 
neuropathologists to classify the majority of cases into 
categories that are compatible with the clinical findings. 
We suggest that the LPC system should be the standard 
future approach for the basic post-mortem evaluation of 
LP in individuals with and without concomitant neurode-
generative diseases.
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